Highlights and Quick Summary
- Net Aquisitions for the quarter ending December 31, 2016 was $0 (a NaN% decrease compared to previous quarter)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Net Aquisitions of Allena Pharmaceuticals, Inc.Most recent Net Aquisitionsof ALNA including historical data for past 10 years.
Interactive Chart of Net Aquisitions of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. Net Aquisitions for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Business Profile of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.